COLLEGIUM PHARMACEUTICAL, INC - Common Stock, par value $0.001 per share

Q: What does CUSIP 19459J104 represent in this 13F holders report?

CUSIP 19459J104 is the security identifier for 19459J104 - COLLEGIUM PHARMACEUTICAL, INC - Common Stock, par value $0.001 per share used to aggregate holder disclosures.

Q: How many institutions held 19459J104 - COLLEGIUM PHARMACEUTICAL, INC - Common Stock, par value $0.001 per share in Q3 2024?

1 institutional investor reported 19459J104 - COLLEGIUM PHARMACEUTICAL, INC - Common Stock, par value $0.001 per share for Q3 2024. Use the holders table for investor-level position and value details.

CUSIP: 19459J104

Q3 2024 13F Holders as of 30 Sep 2024

Type / Class: Equity / Common Stock, par value $0.001 per share
Shares outstanding: 32,219,241
Total 13F shares: 1,373,326
Share change: -6,627
Total reported value: $53,065,317
Price per share: $38.64
Number of holders: 1
Value change: -$256,067
Number of sells: 1

Quarterly Holders Quick Answers

What is CUSIP 19459J104?
CUSIP 19459J104 identifies 19459J104 - COLLEGIUM PHARMACEUTICAL, INC - Common Stock, par value $0.001 per share in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Next holder-history checks

These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.

Back to full security ownership history for the broader multi-quarter picture.
Latest 13F filings for newly reported positions across managers.
Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
SEC investors directory for manager drilldown.

Explore More Reporting Periods

Jump to adjacent filing periods for faster comparison and easier crawl discovery.

Newer quarter: Q4 2025
Previous quarter: Q2 2024

Recent filing periods for CUSIP 19459J104:

Q1 2026 Q4 2025 Q3 2024 Q2 2024 Q1 2024 Q4 2023

Top shareholders of 19459J104 - COLLEGIUM PHARMACEUTICAL, INC - Common Stock, par value $0.001 per share (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.

Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

Holder	Source	Role / Reporting	Ownership %	Shares	Holdings Value	12M Net Δ	As of	Details
BlackRock Finance, Inc.	13F	Company	18%	5,793,383	$186,546,932	—	30 Jun 2024	13F
RENAISSANCE TECHNOLOGIES LLC	13F 13D/G	Company	5.1% from 13D/G	1,531,498	$49,314,236	—	30 Jun 2024	13F 13D/G
STATE STREET CORP	13F	Company	4.3%	1,379,953	$44,434,487	—	30 Jun 2024	13F
CITADEL ADVISORS LLC	13F	Company	0.54%	172,670	$5,559,974	—	30 Jun 2024	13F

Institutional Holders of COLLEGIUM PHARMACEUTICAL, INC - Common Stock, par value $0.001 per share as of Q3 2024

As of 30 Sep 2024, COLLEGIUM PHARMACEUTICAL, INC - Common Stock, par value $0.001 per share was held by 1 institutional shareholder that filed Form 13F with the SEC. Together, they reported ownership of 1,373,326 shares. The largest 3 holders included RENAISSANCE TECHNOLOGIES LLC, STATE STREET CORP, and CITADEL ADVISORS LLC. This page lists 3 institutional shareholders reporting positions in this security for the Q3 2024 filing period.

Investor	Option	Weight %	Change %	Value $	* Price	Shares	Share Change	Activity	Report Period

Compare Q3 2024 vs Q2 2024 Across Filers

Q2 2024 holders

Q3 2024 holders

Holder diff

-1

Investor	Q2 2024 Shares	Q3 2024 Shares	Share Diff	Share Chg %	Q2 2024 Value $	Q3 2024 Value $	Value Diff $	Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend

Quarterly Value Trend

Quarterly Shares Trend

* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.